Abstract
Background: Sarcopenia is progressive loss of muscle mass and strength; this may cause increased morbidity and mortality. Rheumatic diseases as spondyloarthropathies have greater risks of developing sarcopenia.
Objectives: Assessment of sarcopenia in Egyptian patients with psoriatic arthritis (PSA) and axial spondyloarthritis (axSPA) and investigate the relation between sarcopenia and different factors.
Methods: This study included 56 PSA (Group I), 58 axSPA patients (Group II), and 60 healthy controls (Group III). Demographic data were collected, disease activity was assessed using Disease Activity Index for Psoriatic Arthritis (DAPSA) score for PSA patients and ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score) for axSPA patients. Functional assessment was done using Bath ankylosing spondylitis functional index (BASFI) for axSPA patients and Health Assessment Questionnaire (HAQ) for PSA patients. Sarcopenia was assessed by measuring Muscle mass, muscle strength and physical performance.
Results: There was no significant difference between study groups regarding age, and BMI. None of the studied patients had definite sarcopenia, twelve PSA patients (21.43%), and fifteen axSPA patients (25.86%) had probable sarcopenia. While seven PSA, and five axSPA patients had pre-sarcopenia.
We found significant differences between PSA and controls regarding muscle quantity, muscle strength, and muscle performance. While we found significant differences between axSPA and controls regarding muscle strength, and muscle performance. the risk of probable sarcopenia in axSPA patients increased with increasing age and ASDAS-CRP and in PSA patients it increased with increasing age, DAPSA and HAQ.
Conclusions: probable sarcopenia was significantly increased in PsA and axSPA. Our analysis suggests that age, and disease activity were associated with the development of sarcopenia in PSA and axSPA.
References
- Tournadre A, Vial G, Capel F et al. Sarcopenia. Joint Bone Spine. 2019;86(3):309-314. doi:10.1016/j.jbspin.2018;08.001.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on Sarcopenia in older people. Age Ageing 2010; 39(4):412-423.
- An HJ, Tizaoui K, Terrazzino S et al. Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. Int J Mol Sci 2020; 21(16):5678.
- Bhasin S, Travison TG, Manini TM et al. Sarcopenia definition: the position statements of the Sarcopenia definition and outcomes consortium.J Am Geriatr Soc. 2020; 68(7):1410–1418.
- El Miedany Y, El Gaafary M, Gadallah N et al. Sarcopenia in Egypt: epidemiology of sarcopenia risk among older adults presenting with fragility fractures – an initiative by the Egyptian Academy of Bone Health. Egypt Rheumatol Rehabil. 2023;50, 62.
- Cruz-Jentoft AJ, Bahat G, Bauer J et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.
- Targo ska-St pniak B, Majdan M. Associations between parameters of nutritional status and disease activity in patients with rheumatoid arthritis. Pol Arch Med Wewn 2011; 121: 122-128.
- Saraux A, Guillemin F, Guggenbuhl P et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005;64(10):1431-1435.
- Aguiar R, Sequeira J, Meirinhos T et al. SARCOSPA – Sarcopenia in spondyloarthritis patients. Acta Reumatol Port 2014;39(4):322-326.
- Barone M, Viggiani MT, Anelli MG et al. Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. J Clin Med. 2018;1,7(12):504. doi: 10.3390/jcm7120504.
- El Maghraoui A, Ebo’o FB, Sadni S et al. Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis? BMC Musculoskelet Disord 2016;17:268 doi: 10.1186/s12891-016-1155-z.
- Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W. Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis. Reumatologia 2017;55(5):215-221.
- Taylor W, Gladman D, Helliwell P et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73. DOI: 10.1002/art.21972.
- Rudwaleit M, van der Heijde D, Landewé R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection Annals of the Rheumatic Diseases. 2009;68:777-783.
- Schoels M, Aletaha D, Funovits J et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.Ann Rheum Dis. 2010;69(3),1441–1447. DOI: 10.1136/ard.2009.122259.
- Van der Heijde D, Lie E, Kvien TK et al. Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8. doi: 10.1136/ard.2008.100826.
- Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol, 1994;21:2281-5.
- Anderson J, Sayles H, Curtis JR et al. Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010;62(10):1481-8. doi: 10.1002/acr.20265.
- Roberts HC, Denison HJ, Martin HJ et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423-9. doi: 10.1093/ageing/afr051.
- Dodds RM, Syddall HE, Cooper R et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014;4;9(12):e113637. doi: 10.1371/journal.pone.0113637.
- Dodds RM, Murray JC, Granic A et al. Prevalence and factors associated with poor performance in the 5-chair stand test: findings from the Cognitive Function and Ageing Study II and proposed Newcastle protocol for use in the assessment of sarcopenia. J Cachexia Sarcopenia Muscle. 2021;12(2):308-318. doi: 10.1002/jcsm.12660.
- Lee RC, Wang Z, Heo M et al. Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr. 2000;72(3):796-803. doi: 10.1093/ajcn/72.3.796.
- Cruz-Jentoft AJ, Bahat G, Bauer J et al Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;1;48(1):16-31. doi: 10.1093/ageing/afy169.
- Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0 student ed. Wadsworth, Cengage Learning, Belmont, 2013.
- Neto A, Pinheiro Torres R et al. Muscle dysfunction in axial spondylarthritis: the MyoSpA study. Clin Exp Rheumatol. 2022;40(2):267-273. doi:10.55563/clinexprheumatol/9ljng7.
- Öztürk Ö, Feyzioğlu Ö, Şahin D et al. AB1809-HPR determination of PRE-sarcopenia in patients with axial spondyloarthritis Annals of the Rheumatic Diseases. 2023;82:2137.
- Merle B, Cottard M, Sornay-Rendu E et al. Spondyloarthritis and Sarcopenia: Prevalence of Probable Sarcopenia and its Impact on Disease Burden: The Saspar Study. Calcif Tissue Int. 2023;112(6):647-655. doi:10.1007/s00223-023-01074-3.
- Sahin N, Ozcan E, Baskent A et al. Isokinetic evaluation of ankle muscle strength and fatigue in patients with ankylosing spondylitis. Eur J Phys Rehabil Med. 2011;47(3):399-405.
- Valido A, Crespo CL, Pimentel-Santos FM. Muscle Evaluation in Axial Spondyloarthritis-The Evidence for Sarcopenia. Front Med (Lausanne). 2019;18,6:219. doi: 10.3389/fmed.2019.00219.
- Teneva T, Georgiev T. Evaluation of paravertebral muscle atrophy and fatty degeneration in patients with axial spondyloarthritis. Rheumatology (Bulgaria), 2020; 28(3), 25-38. https://doi.org/10.35465/28.3.2020.pp25-38

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.